Company intelligence / Profile preview

Alkyon Therapeutics

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Alkyon Therapeutics is developing a pipeline of next-generation precision-targeted radiopharmaceutical therapies and immunotherapies for solid tumors. The company leverages modular antibody engineering and advanced analytics of the tumor microenvironment to uncover and prosecute novel ECM and stroma-related targets. It currently collaborates with Debiopharm and Nona Biosciences to apply its antibody scaffold and targeting strategies to radioligand and immunotherapeutic development, focusing on preclinical-stage innovation.

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalMonoclonal antibodyAntibody-drug conjugateImmunotherapy
Industry: Biotech

Partnerships

DebiopharmNona Biosciences

Beyond the preview

Go deeper on Alkyon Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alkyon Therapeutics.

Explore the full profile